Romosozumab efficacy and safety in European patients enrolled in the FRAME trial.

Bente Lomholt LangdahlLorenz C HofbauerSerge FerrariZhenxun WangAstrid Fahrleitner-PammerEvelien GielenPéter LakatosEdward CzerwinskiEsteban Jódar GimenoJen TimoshankoMary OatesCesar Libanati

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2022)

Among European patients in FRAME, romosozumab resulted in early and sustained risk reduction for all major fracture categories, associated with large BMD gains that continued after transition to denosumab.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
patient reported outcomes
randomized controlled trial
body composition
bone mineral density
patient reported